TY - JOUR T1 - Local Aromatase Activity Alterations in Breast Cancer Tissues: A Potential Way of Decision Support for Clinicians JF - medRxiv DO - 10.1101/2020.06.04.20122101 SP - 2020.06.04.20122101 AU - Mete Bora Tuzuner AU - Tulin Ozturk AU - Sennur Ilvan AU - Hande Turna AU - Turkan Yurdun AU - Hulya Yilmaz-Aydogan AU - Oguz Ozturk Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/05/2020.06.04.20122101.abstract N2 - Background and aims It is becoming evident that local estrogen exposure is important in postmenopausal breast cancer patients. The microenvironment is established by breast stromal cells based on communication with tumor cells that is essential to cancer development, invasion, and metastasis. Here we investigated aromatase activity levels in both tumor and matched stromal tissues by showing their impact on the manufacturing of local estrogen and tumor progression in cases of invasive ductal carcinoma (IDC).Methods Tumor (T) and tumor-associated stroma (TAS) neighboring tissues were acquired from each postmenopausal patient, diagnosed with IDC, and categorized as luminal A (n = 20). The control group was formed from tumorfree breast tissue samples (N, n = 12). A microsomal-based technique was created to compare breast tissue aromatase activities using liquid chromatography – mass spectrometry.Findings We observed that the TAS tissues have the highest aromatase activities (p < 0.05). High progesterone receptor (PR) intensity levels were found to be decreasing the activity level in these tissues significantly (p< 0.05). Tumor tissue specific aromatase activity levels of postmenopausal patients’ were tend to be lower compared to healthy premenopausal subjects’ (3 fold, p< 0.001). In addition low activity in tumor tissues were associated with low grade and late stage cancers.Conclusions Early detection and personalized therapy is essential for postmenopausal breast cancer patients. Together, our inhouse tandem mass spectrometry technique has the potential for further development and standardization for the measurement of aromatase activity and may assist clinicians decide on therapy policies for postmenopausal IDC patients which could be an invaluable asset for precise and specific evaluation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by the Scientific Research Projects Coordination Unit of Istanbul Technical University [grant number 36004].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Istanbul University School of Medicine and with the 1964 Helsinki declaration. All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (The Scientific Research Projects Ethical Board of Istanbul University School of Medicine, no: 2011/1808-804)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.AIAromatase inhibitorAktProtein kinase BAUCArea under the curveE1EstroneE217-beta estradiolEDTAEthylenediaminetetraacetic acidEREstrogen receptorERKExtracellular signal-regulated kinaseG-6-PGlucose-6-phosphateGFGrowth FactorHER2Human epidermal growth factor receptor 2HPLCHigh pressure liquid chromatographyIDCInvasive ductal carcinomaIGF-IRInsulin-like growth factor 1 receptorIL-11Interleukin-11LCLiquid chromatographyMeOHMethanolMISSMembrane-initiated steroid signalingMRMMultiple reaction monitoringMSMass spectrometrymTORMammalian target of rapamycinMUMannwhitney U testNHealthy breast tissueNISSNuclear-initiated steroid signalingPBSPhosphate buffered salinePI3KPhosphoinositide 3-kinasePRProgesterone receptorSERMSelective ER modulatorSPESolid phase extractionTTumorTASTumor-associated stromaTMETumor microenvironmentTNF-alphaTumor necrosis factor alphaWSRWilcoxon signed-rank test ER -